Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Common Equity (2023 - 2025)

Rallybio's Common Equity history spans 3 years, with the latest figure at $63.0 million for Q3 2025.

  • For Q3 2025, Common Equity fell 10.99% year-over-year to $63.0 million; the TTM value through Sep 2025 reached $63.0 million, down 10.99%, while the annual FY2024 figure was $61.7 million, 41.94% down from the prior year.
  • Common Equity for Q3 2025 was $63.0 million at Rallybio, up from $46.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $155.2 million in Q1 2023 and bottomed at $46.0 million in Q2 2025.
  • The 3-year median for Common Equity is $80.0 million (2024), against an average of $89.9 million.
  • The largest annual shift saw Common Equity plummeted 42.7% in 2024 before it fell 10.99% in 2025.
  • A 3-year view of Common Equity shows it stood at $106.2 million in 2023, then tumbled by 41.94% to $61.7 million in 2024, then grew by 2.24% to $63.0 million in 2025.
  • Per Business Quant, the three most recent readings for RLYB's Common Equity are $63.0 million (Q3 2025), $46.0 million (Q2 2025), and $54.1 million (Q1 2025).